NASDAQ NMS - GLOBAL MARKET · JSPR
+1.77% · +$0.0100 · Vol 365.5K
Market closed · last close 4:00 PM ET · price as of 19:30:58 ET
Jasper Therapeutics Inc

Jasper Therapeutics Inc

Biotechnology
$0.5700
Card
Relationship Map

Follow $JSPR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $JSPR by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
JSPR
Jasper Therapeutics Inc
Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

63/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is JSPR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading JSPR catalysts
About Jasper Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
22
Country
US

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.5433
Day high
$0.5900
Day low
$0.5401
Previous close
$0.5601
52W high
$2.60
-78.08% from high
52W low
$0.3410
10% of range
Market cap
$18.6M
EPS
$-1.5797
Beta
1.62
Shares out
33.3M
Volume
365.5K
1.01× rel vol
Avg volume
361.3K
VWAP
$0.5685
Price history computed in-house
1W
-4.68%
1M
-19.65%
3M
-1.64%
1Y
-76.25%
YTD
-68.85%
SMA 50 $0.6727 · below
SMA 200 $0.9577 · below
52W position 10%

JSPR overview

Veridion Score
63
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around JSPR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading JSPR Form 4 filings
Public disclosures

Congress activity in JSPR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

JSPR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for JSPR in this window.
Lobbying spend

JSPR lobbying filings, year to date.

Registered lobbying filings matched to Jasper Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for JSPR in this window.
Loading news for JSPR
Analyst ratings
Sovereign unlock shows live analyst consensus for JSPR.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.